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Abstract: 
All organisms are subjected each day to changes in the light intensity generated by the Earth’s 
rotation around its own axis. To anticipate this geo-physical variability, and to appropriately 
respond biochemically, most species, including mammals, have evolved an approximate 24-hour 
endogenous timing mechanism known as the circadian clock (CC). The ‘clock’ is self-sustained, 
cell autonomous and present in every cell type. At the core of the clock resides the CC-oscillator, 
an exquisitely crafted transcriptional-translational feedback system. Remarkably, components of 
the CC-oscillator not only maintain daily rhythmicity of their own synthesis, but also generate 
temporal variability in the expression levels of numerous target genes through transcriptional, 
post-transcriptional and post-translational mechanisms, thus, ensuring proper chronological 
coordination in the functioning of cells, tissues and organs, including the liver. Indeed, a variety 
of physiologically critical hepatic functions and cellular processes are CC-controlled. It is not 
surprising then, that the modern lifestyle (e.g. travel and jet lag, night and rotating shift work), 
which force ‘circadian misalignment’ have emerged as major contributors to global health 
problems including obesity, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). 
Here, we provide an overview of the CC-dependent pathways which play critical roles in mediating 
several hepatic functions under physiological conditions and, whose deregulations are implicated 
in chronic liver disease including NASH and alcoholic liver disease (ALD).  
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Introduction 
The word circadian is Latin in origin, and translates to ‘about a day’, hence, oscillations of ~24 
hours are referred as circadian rhythms. These rhythms are generated by the Earth’s 24 hours 
rotation, which, in turn drives the light-dark cycle. This daily change in the light intensity leads to 
overt rest-activity and feeding-fasting cycles, e.g. human beings are diurnal and conduct most of 
their activities during the day and rest at night. Teleologically, these rhythms have allowed 
organisms to anticipate changes in the external environment (e.g. the light-dark cycle), and to 
respond by adjusting CC-driven physiological functions, e.g. metabolism (1-7). Accordingly, the CC-
controlled behavioral synchronization with feeding-fasting cycles generates diurnal variations in 
metabolic activities, which, in turn, ensures energy homeostasis. Recent investigations have 
established that, in mammals, the expression of numerous genes in different organs (including 
the liver) display circadian rhythmicity, which enables regulation of both anabolism and catabolism 
(1-6). Indeed, hepatocyte activities such as nutrient uptake, processing, assimilation and 
detoxification exhibit remarkable diurnal variations, which enable their alignment with food 
availability and energetic demand. Physiologically these ‘metabolic rhythms’ are generated and 
maintained by the dynamic interactions between the CC and timing cues e.g. light and food (time 
of eating and its quality). However, our modern lifestyle (jet lag, shift-work, energy-dense foods 
etc.), which often ‘misaligns’ CC functioning has recently emerged as prominent contributors to 
different metabolic diseases and carcinogenesis (8-13). 
     Here, we focus on how the CC regulates hepatic metabolism to maintain homeostasis and, 
also provide an overview of how deregulation of CC-controlled pathways could lead to the 
development of non-alcoholic fatty liver (NAFL) and its progression to NASH. Furthermore, we 
also discuss evidences linking the CC and alcohol-induced liver disease (ALD). 
 
The anatomic and molecular organization of the mammalian CC-system 
Retinal photoreceptors (rods and cones) transform photic energy to electrical impulses and 
convey them to the brain through retinal ganglion cells (RGC). A subset of RGCs expressing the 
photopigment melanopsin are intrinsically sensitive to the visible spectrum and directly relay the 
photic signal to a hypothalamic region called the suprachiasmatic nucleus (SCN) (7-8). Hence, 
anatomically, the mammalian circadian system is hierarchical, whereby the light-entrained SCN 
is the ‘central’ CC. In turn, the SCN-CC by utilizing humoral and neuronal mechanisms 
communicates the ‘time cue’ (a. k. a; ‘Zeitgeber’; ZT) to other organs, thereby enabling the 
synchronization of peripheral CCs (PCCs) (1-8).  
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       At the molecular level, the components of the central SCN and PCCs are the same and are 
identically organized in multiple transcriptional-translational feedback systems (Figure 1) and 
generate a cell autonomous self-sustained CC-oscillator with a periodicity of ~24 hours (1-6). The 
heart of this oscillator is constituted by a heterodimer of transcription factors (TFs), the Brain and 
Muscle ARNTL-Like protein1 (BMAL1) associated with the Circadian Locomotor Output Cycles 
Kaput (CLOCK), which activate genes containing E-Box DNA Binding Sequences (DBS) in their 
promoter-enhancer regions, including those of Period (Per1, Per2) and Cryptochrome (Cry1, 
Cry2) genes. In turn, PER1/2 and CRY1/2 proteins heterodimerize to inhibit the transcriptional 
activity of the BMAL1/CLOCK-complex (the first-loop of the oscillator), thereby eventually 
suppressing their own expression (Figure 1). BMAL1/CLOCK-also binds to the E-Box DBSs 
present in the genes of the nuclear receptors Rev-Erbα and Rev-Erbβ to activate their 
transcription, while the presence of RORE DBSs in the Rev-Erbα/β genes mediate their 
autorepression. REV-ERBs also inhibit (through RORE DBSs) the transcription of their activators 
Bmal1 and Clock, thus constituting the second-loop of the CC-oscillator. At the beginning of the 
active phase, levels of REV-ERBs (which are repressors of transcription) decrease, while 
simultaneously protein levels of transcriptional activators RORα/γ increase, which then bind to 
RORE DBSs present in Bmal1 and Clock and activate their transcription, thereby initiating the 
next round of CC oscillation. Additionally, BMAL1/CLOCK-induces expression of the trans-
activator D-Box binding protein (Dbp). The DBP activator and the E4BP4 repressor (which is 
activated by RORα/γ and repressed by REV-ERBα) competes for binding to D-Box DBSs present 
in several CC-controlled genes (CCGs).These inter-connected feed-back loops generate 
circadian oscillations of the expression of ~20% of the genome, such that CCGs containing RORE 
DBS are transcribed during the active phase, while E-Box and D-Box DBS-bearing genes are 
expressed during the rest phase(1-6,14). Moreover, post-translational modifications of CC-
components also aids in further fine-tuning of the CC-oscillator functioning. Thus, utilizing multiple 
mechanisms the CC-oscillator drives a temporally-restricted gene expression pattern, which lies 
at the core of generating distinct biochemical outputs in individual organs.  
 
Feeding cycles and peripheral clocks 
Establishment of feeding cycles as the prominent zeitgeber for peripheral tissues, including the 
liver (15-16), has revealed the existence of extensive cross-talk between metabolism and the CC, 
and the list of mechanisms through which metabolic signals influence CC functioning and, vice 
versa, are increasing rapidly (1-5). The dominance of feeding cycles on the liver-clock was 
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demonstrated in ‘arrhythmic’ Cry1/2 mutant mice, in which an imposed feeding regime recovered 
‘rhythmicity’ in circadian gene expression pattern (17). Furthermore, changing the feeding time from 
active to rest phases in mice shifts the PCCs by ~12 hours (15-16), driven by metabolic alterations 
acting through PPARα and CREB (18). Notably, high-fat diet (HFD)-induced ‘reprogramming’ of 
the hepatic CC (19) can be prevented by restricting HFD feeding during the active phase (20). One 
physiological example of CC-metabolism crosstalk is provided by BMAL1/CLOCK-dependent 
transcription of the nicotinamide phosphoribosyl transferase (NAMPT) gene, which is involved in 
NAD+ synthesis (21-22). CC-dictated NAMPT expression ensures not only a rhythmicity in NAD+ 
synthesis but also regulates the activities of NAD+ -dependent proteins (1-5), e.g. the SIRT1 
deacetylase and the ADP-ribosyltransferase PARP-1. In turn, SIRT1 determines: (i) the activity 
of BMAL1/CLOCK-complex towards their target genes and, (ii) the stability of PER2 protein, which 
together maintain CC-oscillator functioning (1-5). Akin to NAD+, feedback regulation between the 
CC and heme biosynthesis has also been demonstrated (23-24). Thus, by controlling metabolite 
sensors (NAD+, heme etc.), the CC gauges the cellular energetic and redox status to reset the 
oscillator with metabolism. Altogether, these investigations have established metabolism as a 
critical modulator of PCCs. 
 
Circadian regulation of hepatic functions 
Given the centrality of the liver in maintaining whole-body physiology, several high-throughput 
circadian time-course studies have been performed in mouse models investigating cistrome (25-
28), transcriptome (29-30), proteome (31-33), and lipidome (34-35). Circadian transcriptome analyses 
have revealed two broad crests of transcription in liver, corresponding to the transition between 
successive active and rest phases (1-5). Cistromic analyses (25-28) revealed that these two distinct 
mRNA repertoires are generated due to the rhythmicity of the CC-oscillator, which enables 
periodic recruitment/removal of TFs and coregulators to epigenetically alter the chromatin 
landscape of CCGs. Cellular processes like DNA repair, ribosome biogenesis, autophagy, ER-
stress are also subjected to circadian regulation, but mainly at the post-translational level (31-33). 
Altogether, these investigations have revealed an unprecedented level of CC-control on hepatic 
physiology (Figure 2). Importantly. deregulation of these CC-regulated pathways/processes has 
been shown to contribute to the development of NAFLD and other diseases. 
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The circadian clock and pathophysiology of NAFLD and NASH 
Over the last decades, life-style changes have shifted health care priorities world-wide from 
infectious to metabolic diseases (36-38). In the context of liver disease, vaccination can now prevent 
hepatitis B virus (HBV) infection and antivirals can control chronic HBV infection (39-40,43), and 
recently developed direct-acting antivirals can cure chronic hepatitis C virus in a large majority of 
infected patients (41-43). In contrast, the prevalence of metabolic liver diseases such as NAFL and 
NASH are increasing dramatically in conjunction with obesity and type II diabetes (36-38,44). NAFLD, 
is a continuous spectrum of disease initiated by excessive triglyceride (TG) accumulation in the 
liver. In the absence of concomitant inflammation and hepatocytic injury, this state is largely 
benign and commonly referred as nonalcoholic fatty liver (NAFL) or simple steatosis (36-38, 45). 
However, chronic NAFL usually drives simple steatosis to steatohepatitis (NASH), which is 
typified by concomitant presence of both lobular inflammation and hepatocellular damage 
(ballooning). Moreover, NASH predisposes to fibrosis, progressing to cirrhosis and hepatocellular 
carcinoma (HCC) (36-38). Like every other aspect of the metabolic syndrome, development of 
NAFLD and NASH is highly complex which has been reviewed extensively elsewhere (36-38,46-48). 
Almost two decades earlier the ‘two-hit’ theory (49) was posited to explain NASH pathogenesis. 
This theory proclaimed that unrestrained TG deposition in the liver (first-hit; NAFL) leads to 
‘secondary hits’ such as oxidative stress, which ultimately leads to NASH. However, with 
increasing knowledge of metabolism and associated pathologies, NAFLD is now considered as a 
multi-factorial systemic metabolic disorder (36-38). Indeed, investigations have revealed crucial 
roles for intestine, adipose tissue and muscle in NAFLD development. Importantly, insulin 
resistance also plays a critical, if not indispensable role in NAFLD (36,38,45).  
    Systemic energy homeostasis is maintained by communications between numerous intra- and 
inter-organ signaling networks and at the core of NAFLD pathogenesis lies the inability of the liver 
to effectively metabolize carbohydrates and fatty acids (36-38, 50). The pathology of NAFLD is 
generally initiated by perturbations in free fatty acid (FFA) metabolism, which drives excessive 
TG accumulation in hepatocytes (36-37). Increased FFA release from adipocytes due to insulin 
resistance (51) and conversion of excess carbohydrates to FFA via hepatic de novo lipogenesis 
(DNL) (52) are two major sources of TG deposition during NAFLD development, in addition to 
excess caloric intake. In hepatocytes, FFA can either undergo β-oxidation or be re-esterified as 
TG. In turn, this pool of TG can either be exported as VLDL particles or stored in lipid droplets (36-
38). The capacity to metabolize FFA through either β-oxidation or TG formation when overwhelmed 
(perturbation of dynamic lipid fluxes), leads to the accumulation of lipotoxic species. This buildup 
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of lipotoxic molecules in turn damages hepatocytes through several pathways; e.g. enhanced ER- 
and oxidative- stress, a dysfunctional unfolded protein response (UPR), and inflammosome 
activation to finally lead to NAFLD development (37,50,53-54). In the subsequent sections we describe 
some of these hepatic functions and processes which show diurnal variations and whose 
deregulation could predispose towards NAFLD/NASH (Figure 3). 
 
Circadian control of glucose metabolism 
The liver is the principal gluconeogenic organ in mammals, and participates, along with several 
other organs, to maintain homeostatic blood glucose levels. The CC sustains the physiological 
levels of blood glucose by synchronizing tissue-specific mechanisms of glucose metabolism. 
Accordingly, the SCN-clock controls the feeding/fasting rhythms, while PCCs (liver, pancreatic β-
cells, skeletal muscles) drive temporally coordinated gene expression programs to maintain 
physiological levels of glucose in blood (55).  
    One of the first studies indicating a role for the liver-CC-oscillator in glucose metabolism 
showed that Bmal1 ablation in hepatocytes reduced expression of the glucose transporter (Glut2), 
leading to a decreased post-absorptive glucose uptake in mutant mice (56). Post-hepatocytic entry, 
glucose is phosphorylated to glucose-6-phosphate (G6P), which can be either used (through 
glycolysis or hexose monophosphate pathway) or stored (glycogen synthesis). Remarkably, the 
CC influences all these processes (2,6). For example, the hepatic expression of glucokinase (Gck), 
which controls both glycolysis and glycogen synthesis is rhythmic reaching its zenith during the 
transition from the rest-phase to the active-phase (17, 57) and temporally matches the surge of post-
prandial insulin secretion from the pancreas. This increase in insulin secretion also leads to a 
pulsatile glycogen synthase kinase 3 (GSK3) activity in liver (17), which, in turn, determines: (i) the 
enzymatic activity of glycogen synthase, (ii) the activity of the glycosylating enzyme O-linked N-
acetylglucosamine transferase (OGT), thereby, generating rhythmicity in the glycosylation levels 
of numerous proteins (58) and, (iii) the stability of REV-ERBα (2,4), which in turn dictates the 
expression of many CCGs. By controlling the expression of trans-activators Klf10 (59) and Hnf4α 
(60), the liver-CC further dictates transcription of several genes, which are involved in glucose 
metabolism.  
      The CC also controls glucagon-induced gluconeogenesis in liver by regulating the duration of 
hepatic cAMP production (61). It was demonstrated that the interaction of the CC-component CRY1 
with the regulatory α-subunit of the glucagon receptor blocks hepatic cAMP accumulation during 
the circadian active phase, thus leading to a temporally-restricted (between rest- and active-
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phases) activation of the gluconeogenic transcription factor CREB (55,61). Moreover, BMAL1-
regulates the expression of the Pgc1α gene (62), which is a coactivator of the gluconeogenic 
transcription program (2-4). Thus, by employing multiple strategies the CC controls diverse 
mechanisms which co-operate to maintain physiological glucose levels (1-5, 55).  
 
Circadian regulation of liver lipid metabolism 
In a seminal study, Turek et al. (63) demonstrated that Clock mutant mice are obese and have 
increased blood levels of cholesterol and TG. Since then, multiple genetic studies in mice models 
have established the CC as a critical regulator of lipid metabolism (64-66). Indeed, plasma levels of 
FFA, TG and cholesterol display diurnal variations, and are altered upon mutations of CC-
components. Notably, the liver plays a crucial role in generating these variations in blood levels. 
Indeed, hepatocyte-specific ablation of Rev-Erbα/β was found to increase plasma levels of FFA, 
TG and cholesterol (27,66).  In this regard, a lipidomic study revealed that TG, phosphatidyl inositol 
and phosphatidyl choline preferentially accumulate in mouse liver during the rest phase (35). 
Mechanistically, the CC controls enzymes that are critically involved in regulating various steps 
of lipid metabolism. As example, expression of the enzyme ATP citrate lyase, which drives 
mitochondrial export of acetyl Coenzyme A (acetyl CoA), is maximal at the beginning of the active 
phase (17). Cytosolic acetyl CoA is carboxylated by acetyl CoA carboxylase (ACC1) to generate 
malonyl CoA an essential step in fatty acid synthesis. It is well known that AMPK inactivates ACC 
by phosphorylation (2-4), and CCs by controlling AMPK ‘temporally gate’ ACC activity (67). 
Furthermore, the liver CC by controlling the transcription of Elovl3, Elovl6, Fas etc. ‘times’ fatty 
acid synthesis (2-6). Moreover, the expression of enzymes regulating β-oxidation (Cpt1/2) and 
ketone-body production (Hmgcs2) (68-69), as well as their transcriptional regulators PPAR α and δ 
are also circadian in nature (60).  
    Hepatic TG synthesis from glycerol-3-phosphate is a multistep process and expression of 
several genes (Gpat2, Agpat1/2, Lipin1/2 and Dgat2) that regulate successive steps of TG 
synthesis is circadian in nature (35). Importantly, by controlling the transcription of Pnpla3 the CC 
also regulates lipid droplet dynamics (35). Altogether, in ad libitum fed mice livers, a prominent 
crest and trough of TG levels are observed during the rest (~ZT8) and active phases (~ZT20). 
Additionally, REV-ERBα-controlled expression of Insig2 regulates the activity of SREBP1c, 
thereby leading to CC-command over lipogenesis (70).  
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Clock and metabolism of bile acids 
Intestinal absorption of lipids requires bile acids (BA), which are synthesized in hepatocytes. 
Besides lipid absorption, recent evidences have established BA as signaling molecules (71-72). BA 
are physiological ligands for FXR and the G-protein coupled receptor TGR5 and can activate 
signaling modules such as the MAPK-pathway (71-72). By regulating these diverse signaling 
networks, BA not only control their own levels but also those of TG, cholesterol and glucose 
homeostasis (71-72). BA synthesis is controlled by a transcriptional feed-back loop consisting of the 
nuclear receptors FXR and SHP and hormone FGF15 (FGF19 in humans) (38,73). Hepatic 
expressions of both FXR and SHP (60) and the intestinal secretion of FGF15 are ‘clock’-gated (74), 
which, together, drive the circadian transcription of cholesterol 7α-hydroxylase (Cyp7a1), the rate-
limiting enzyme in the classical BA synthesis pathway. Moreover, the CC-output regulator DBP 
controls Cyp7a1 transcription to restrict its temporal expression (75). Additionally, by regulating the 
transcription of both E4BP4 and SHP, REV-ERBα directly regulates the expression of Cyp7a1. 
(76) Altogether, these mechanisms cooperatively generate diurnal rhythmicity in BA levels (Figure 
3), which is also observed in humans (77).  
 
Clock-controlled cellular processes and NAFLD 
Along with controlling systemic metabolism (2-5), several investigations have indicated a critical 
role for the CC-machinery in regulating autophagy, ER stress and oxidative stress (78-80), all of 
which may participate in NAFLD and in its transition to NASH (36-37). For example, in murine livers, 
expression of key genes controlling different steps of the autophagic process display circadian 
rhythms, thereby leading to an overall diurnal rhythm in autophagic activity (78-79). Consistently, 
hepatocytic mutation of Bmal1 impairs the entire autophagic process in murine liver. The CC also 
modulates the ER stress-induced activation of the UPR-driven gene expression program (78,80). 
Physiologically, the UPR is necessary to restore cellular secretory capacity following an 
accumulation of misfolded proteins in the ER and functions by degrading unfolded proteins and 
activating the expression of chaperones which enable protein folding (81). The CC by generating 
ultradian (lesser than a day) rhythms in the expression of UPR master regulators i.e. the inositol-
requiring enzyme1α (IRE1α) and the X-box binding protein1 (XBP1) controls the expression of 
several genes within the UPR pathway (78,80). Moreover, by regulating activation of the 
transcription factor CREBH (82) and expression of the deadenylase CPEB4 (83), the CC extends 
control over the ER-stress response pathway. Deregulation in reactive oxygen species (ROS) 
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production and scavenging have been implicated in the development of NAFLD and NASH. To 
avoid the dangers of excessive ROS levels, cells are dependent on anti-oxidant enzymes. 
Interestingly, expressions and activities of several enzymes, e.g. glutathione reductase, 
superoxide dismutase, glutathione peroxidase and peroxiredoxins display CC-controlled diurnal 
rhythms (84-85). Consistently, in peripheral tissues levels of ROS as well as peroxidized 
lipids/proteins vary per the light-dark cycle (86). Thus, it is evident that the ‘clock’ plays a 
remarkable role in regulating several cellular processes where deregulation have been strongly 
implicated in chronic liver diseases (Figure 3). 
Circadian clock, nuclear receptors (NRs) and NAFLD 
The nuclear receptor (NR) superfamily which comprises 48 members in humans, control diverse 
aspects of physiology including metabolism (87-89). NRs are transcription factors, which upon ligand 
(natural and synthetic) binding drive gene expression programs, amongst whom are pathways 
controlling metabolism. Investigation of the circadian expression patterns of all NRs in four mice 
tissues, including, the liver (60), revealed that at least 20 of the 41 transcribed NR in the murine 
liver are expressed in a circadian manner thereby providing a possible molecular link between 
the clock, NRs, and metabolism. In the liver, NRs control a broad range of crucial hepatic functions 
and are prominently implicated in NAFLD development (38,88-89). Here, we briefly discuss a few of 
these NRs that are not only known to be regulated by the ‘clock’ but also have emerged as 
therapeutic targets for NAFLD (see below). PPARα regulates β-oxidation and ketogenesis (90) and 
plays a prominent role in inflammation by trans-repressing NF-κB and AP-1 pathways (91). 
Importantly, genetic studies in mice indicate that through this trans-repressive activity PPARα can 
prevent fibrosis development which is a crucial event in NASH pathogenesis (91). Ligand activation 
of PPARβ/δ (which plays a prominent role in lipid catabolism) also prevents hepatic fibrogenesis 
(92). The Liver X receptors (LXRs) are transcriptional regulators of cholesterol metabolism and 
hepatic lipogenesis, and LXR activation lowers atherosclerosis by enhancing reverse cholesterol 
transport (89). Whereas LXR could be a possible antifibrotic target (93), LXR- activation enhances 
lipogenesis due to LXR-induced activation of SREBP1c activity (93). Lastly, with the establishment 
of pleiotropic roles of BAs in metabolic regulation, FXR has gained considerable attention as a 
therapeutic target for NAFLD (see below). Indeed, hepatic FXR activation reduces lipogenesis 
and improves fibrosis (72). 
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Clock, gut microbiota and NAFLD 
Besides liver-restricted functions and processes, extrahepatic tissues also play a crucial role in 
NAFLD. Obesity-associated alterations in the gut microbiota (i.e., dysbiosis) composition and their 
interactions with the host (intestinal epithelial cells; IEC) have been implicated as an etiological 
agent in the pathogenesis of metabolic diseases, including NAFLD (94-97). A mechanism through 
which changes in gut microbiota composition may promote NAFLD is through increased LPS 
production and delivery to the liver via the portal circulation (98-99). In turn, microbiota-derived LPS 
can perturb hepatic lipid metabolism by modulating the production of short-chain fatty acids and 
altering the BA pool composition (99), which may influence intestinal and hepatic FXR activity, thus 
affecting both glucose and lipid homeostasis (99). Remarkably, the CC by regulating the expression 
of microbial pattern recognition receptors (e.g. TLRs, NOD2) provides a ‘temporal window’ during 
which microbiota-signals regulate gene expression to maintain homeostasis (100). Interestingly, the 
gut microbiota also displays ‘clock’-controlled diurnal rhythmicity (101-102). Consistently, circadian 
perturbations (mutation of CC-components or jet lag) lead to dysbiosis and development of 
metabolic pathologies (101). Furthermore, mutation of innate immune genes (Tlr5, Nlrp6, Nlrp3) 
which play pivotal roles in sensing gut microbiota, modulate metabolic pathologies, including 
NAFL(95). 
Chronopharmacology: detoxification, pharmacokinetics, and dynamics 
Considering its overall influence on physiology, it is hardly surprising that clinically relevant 
pharmacological aspects, e.g. pharmacokinetics (PK) and pharmacodynamics (PD), of many 
drugs are also governed by the ‘clock’, thereby introducing circadian variations in drug 
metabolism/detoxification and efficacy (84,103). One of the most prominent examples of circadian 
control over pharmacology emerges from its ability to regulate almost every step of xenobiotic 
detoxification in the liver, including absorption, biotransformation and elimination (84,103-104). 
Notably, in humans, hepatic absorption of lipophilic drugs occurs more swiftly in the morning than 
in the evening (103). Consistently, expression of several transport proteins which mediate 
xenobiotic uptake e.g. cationic and anionic transporters (Oct-1, Oatp1, Oatp1a4 etc.) display 
circadian rhythmicity (103). Classically, xenobiotic metabolism is grouped into three (I, II, and III) 
phases. Phase I involves biochemical modification of substrates by the CYP450 superfamily of 
enzymes. Importantly, transcript levels of several members (Cyp2a4, Cyp2a5, Cyp2b10, Cyp2e1, 
Cyp3a11 etc.) of this family are rhythmic, attaining in mouse liver their peak during the rest phase 
(84,104). In phase II, xenobiotics are rendered hydrophilic by conjugation to various small molecules. 
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Notably, phase II controlling genes (Sult1c1, Sult1d1, Gsta1, Gsta2 etc.) are also expressed in a 
circadian manner. The excretion of xenobiotics (phase III) is controlled by different transporter 
proteins, and several of them (Mrp2, Mdr2, Abcg2, Abcc2 etc.) oscillate rhythmically in the mouse 
liver. This pervasive circadian control of all these phases is molecularly achieved by hepatic CC-
driven regulation of TFs, enzymes and transport proteins participating in the detoxification process 
(84,104). Hepatic expression of TFs (PXR, CAR and AhR), which bind and metabolize xenobiotics, 
is rhythmic (60). Moreover, CC-components (RORα/γ) and CC-output regulators (DBP, HLF and 
TEF) also transcriptionally regulate the detoxification process (105-106). Accordingly, mice with 
ablation of the Dbp, Hlf and Tef genes exhibit widespread deficiencies in both basal and inducible 
detoxification processes (106). 
   Circadian control of ‘pharmacology’ extends beyond the liver and has been reviewed elsewhere 
(84,107). ‘Timing’ is of crucial but less-appreciated factor in drug efficacy. Indeed, 56 of the top 100 
best-selling drugs in the USA target the product of a circadian gene (108). However, most of them 
are yet to be associated and dosed as per the circadian rhythm. Importantly, clock perturbations 
resulting from HFD feeding can be rescued by ‘properly-timed’ pharmacological interventions (109). 
Taken together, recent studies (although many in rodent models) suggest that it will be highly 
prudent to investigate the mechanistic basis of circadian variations in PK/PD, in order to include 
a ‘circadian’ component for better therapeutic outcomes (84,107). 
Therapeutic impact: CC and pharmacological targeting of NAFLD 
While licensed pharmacological therapies are not yet available(36-38), a larger number of 
approaches and compounds are in preclinical and clinical development. Most therapeutic 
strategies aim to decrease inflammation, fibrosis, and metabolic substrate availability or to 
increase their disposal from the liver. Weight loss management or bariatric surgery not only 
improves NASH, but can also induce fibrosis regression (38, 110). Considering the key impact of 
CC-control in regulation of metabolism, it is likely that the molecular targets of several drug 
candidates are CC-regulated. For example, obeticholic acid (INT-747) which activates FXR, 
reverses histological features of NASH (111) and the CC is well known to control BA metabolism. 
Interestingly, FGF19 which is rhythmically secreted from intestine (post-feeding) has efficacy in 
murine models of NASH (112). Importantly, treatment with the FGF19 analog NGM282 reduces 
hepatic fat content in NASH patients (113). The CC-regulated NRs PPAR-α/β are activated by 
elafibranor (currently in phase 3 trial), which enhances lipid metabolism, insulin sensitivity and 
reduces inflammation (114). Furthermore, FGF21, a direct transcriptional target of PPARα reduces 
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steatosis (37). Significantly, some other potential NASH-modulating compounds (37-38), e.g. 
resveratrol (SIRT1-agonist), inhibitors of acetyl-CoA carboxylase (ACC) and FAS, further 
strengthen the CC-connection to therapeutics.     
   The intimate relationship between metabolism and the CC, as well as the amenability of the 
CC-oscillator to a variety of ‘resetting’ signals (1-7), has spurred investigations to explore the 
potential of ‘clock’ modulating small molecules as a possible treatment for metabolic disorders 
(115-118). Using high-throughput phenotypic screening or medicinal chemistry approaches several 
molecules affecting the affect circadian period, phase and/or amplitude have been identified (115-
118). Consistent with the molecular-genetic studies revealing a regulatory role for PERs and CRYs 
in CC-functioning, several compounds have been found to affect their levels and alter (mostly 
lengthening) circadian periods (115-117). One such compound, KL001 was found to bind CRY 
proteins which prevented their ubiquitination and proteasomal degradation (116,119). Consistent with 
the known role of CRYs in suppressing gluconeogenesis, KL001 administration was shown to 
improve glucose tolerance in diet-induced obese (DIO) mice (116,120). Recent investigations have 
also identified several modulators of CC-components RORα/γ and REV-ERBα/β with therapeutic 
potential in animal models of metabolic disorders (116-118). In this regard, agonists of REV-ERBs; 
e.g., SR9009 and SR9011 (121), and an inverse ROR agonist of (SR1555) (122) were found to 
improve several metabolic parameters in DIO mice. Amongst identified ROR modulators nobiletin 
(NOB) was demonstrated to enhance the amplitude of the CC, reduce weight gain, improve 
energy homeostasis and metabolic parameters in both DIO and genetically diabetic (db/db) mice 
(116-118, 123). Taken together, these small molecule modulators of CC-components provide an 
opportunity to further reveal regulatory networks in circadian functioning which could be targeted, 
alone or in combination, to treat metabolic liver disease.  
CC and alcohol-induced liver disease (ALD) 
Like NAFLD, pathogenesis of alcohol-induced liver disease (ALD) is complex and arises from 
interactions between metabolic, environmental and genetic risk factors in heavy alcohol 
consumers. In the context of alcohol-related disease, the CC has largely been investigated from 
a neurobehavioral perspective, noting CC disruption in alcohol use disorders and addiction (124-
125). For example, rotating shift-workers have increased alcohol intake and tendencies to engage 
in binge drinking (126). Genetic variants in some clock genes are also associated with alcohol 
dependence and increased drinking in humans (127-128). Finally, transcript levels of CC genes are 
significantly lower in peripheral blood mononuclear cells from alcohol-dependent patients 
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compared with healthy control subjects (129). Together, these studies suggest that CC alterations 
could promote alcoholic disorders and excessive alcohol consumption. 
Investigations using Per2::Luciferase knock-in mice demonstrated that alcohol consumption 
misaligns peripheral clocks from the master SCN clock (130-131). Additionally, in liver, chronic 
alcohol consumption disrupts rhythmic oscillations of several CC components and CC-controlled 
output genes involved in regulating glucose, glycogen, cholesterol, BA and FFA metabolism (130, 
132). For example, chronic alcohol intake in mice alters the diurnal rhythm in hepatic glycogen 
content due to dampened and/or shifted oscillations in glucose and glycogen metabolism genes 
(57, 132) Moreover, liver-specific BMAL1 deletion and chronic alcohol abolish day-night differences 
in hepatic glycogen content (132). Alcohol consumption also disrupts rhythmic oscillations in the 
cofactor NAD+ (130) required for numerous metabolic functions in the liver, including pathways 
regulated by SIRT1 and PARP-1. Furthermore, CC disruption (mutation or disrupting the light-
dark cycle) enhances alcohol-induced tissue injury in mice. For example, alcohol-induced 
steatosis is higher in livers of Clock-mutant mice as compared to wild-type mice (133). Liver-specific 
deletion of BMAL1 also increases hepatic steatosis in mice treated with chronic plus binge alcohol 
(134). Moreover, CC-disruption through weekly 12-h shifts in the light-dark cycle, increases gut 
leakiness and liver injury in alcohol-fed mice (135). Importantly, whole gut and colon permeability is 
enhanced in night-shift but not in day-shift workers who consumed moderate amounts of alcohol 
(0.5 g/kg/day) for only one week (136). Collectively, these studies suggest that CC disruption may 
increase risk for liver disease in alcohol consumers. Importantly, as key mechanisms and linkages 
among alcohol-mediated CC disruption, metabolic dysregulation, and tissue injury emerge, it may 
become possible to pharmacologically target the CC in ALD patients. 
Conclusion and future perspectives 
The pathogenesis of NAFL and its progression to NASH, the most-prevalent noninfectious liver 
disease, is complex and multifactorial. Both genetic factors as well as the environment have been 
shown to play important functional roles. Perturbations in FFA metabolism, which lies at the core 
of NAFLD could potentially arise from deregulation of several distinct mechanisms. Remarkably, 
under physiological conditions most of these processes are governed by the CC-machinery. 
Consistently, in mice models, either mutation of CC-components (1-5) or change in the feeding time 
(137) are closely associated with a range of metabolic diseases including NAFL. Importantly, recent 
investigations have categorically established that in humans ‘circadian misalignment’ has adverse 
metabolic and cardiovascular consequences (138-139). Furthermore, epidemiologically, single 
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nucleotide polymorphisms (SNPs) in the Clock gene (140) and in several CC-controlled 
transcriptional regulators (e.g. Pparγ, Stat3, Ppargc1α) (88) and the enzyme Pnpla3 (141) are 
associated with the development of obesity, metabolic syndrome, NAFLD and NASH. Most 
significantly, our nouveau life-style (nutrient-dense foods, timing of eating and activity) which 
continuously interferes with endogenous circadian rhythms is also epidemiologically correlated 
with increasing incidences of all the hallmarks of metabolic syndrome including, NAFLD (8-12). 
Given the socio-economic realities in modern societies, it is difficult to avoid circadian disruption. 
Thus, in addition to life-style modification, CC-targeting approaches may provide therapeutic 
opportunities overcoming these challenges. Furthermore, comprehensive systems level 
investigations of the circadian system elucidating physical- and genetic-interaction networks will 
reveal novel targets to prevent and treat chronic liver disease. 
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  The recruitment of BMAL1/ CLOCK- heterodimer to the E-Box DBS present in the promoter-enhancer elements of numerous CCGs, 
  including Periods (Per1/2) and Cryptochromes (Cry1/2) augment their expression during the rest phase. Following accumulation,  
  PERs and CRYs proteins dimerize and translocate to inhibit BMAL1/CLOCK-dependent transcription during the active phase. 
  Next, post-translational modifications including ubiquitination induce proteasomal degradation of PERs and CRYs, thus, initiating  
  the next circadian cycle. In the second loop, BMAL1/CLOCK-dependent expression of Rev-Erbα/β during the rest phase, leads to  
  the trans-repression of several RORE-DBS-containing CCGs including, Bmal1, Clock and E4BP4. In the active phase, the reduction  
  in REV-ERBs levels permit the RORα/γ-dependent RORE-mediated activation of CCGs including Bmal1 and Clock, which enables  
  the turning of the circadian clock. Furthermore, DBP expression during the rest phase activates D-Box DBS containing CCGs, which  
  are transcriptionally repressed by E4BP4 during the active phase. These coupled transcriptional-translational regulatory circuits are 
  ubiquitously present in almost all cell types and directly control the expression of a vast number of mammalian genes. 
  CCG-Clock Controlled Genes. E-CCGs: E-Box DBS-containing CCGs, R-CCGs: RORE-containing CCGs,  
  D-CCGs: D-Box-containing CCGs. 
Figure 1. The molecular architecture of the Circadian Clock (CC)-oscillator  
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Figure 2. The clock controls the physiology of liver 
Light-entrained central SCN-clock synchronizes peripheral tissue clocks including that of liver. The 
‘clock’ machinery in turn drives the expression of several key transcription factors, rate limiting enzymes  
and transport proteins to spatiotemporally regulate several biochemical processes, which, together 
maintain physiological homeostasis. The ‘clock’-connections to some of these processes and their 
connections to NAFLD and NASH have been discussed in detail.  
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Model representing a global view of how alterations in circadian clock-controlled ‘rhythmic’ functions/pathways and 
processes could predispose to non-alcoholic fatty liver disease. Knowledge of the mechanisms through which the 
‘clock’-system influences all these systems and essential pharmacological parameters, in turn, could be utilized to 
develop novel chronotherapeutics. Green arrowheads represent activation and red bar-heads represent inhibition. 
See text for details.  
Figure 3. Multidimensional connections of the ‘clock’ to the pathogenesis of fatty liver  
